Immunogenity and antibodies persistance of diphteria-tetanus-acellular pertussis vaccination in adolescent and adults: a sistematic review of the literature showed different response to the available vaccines
pdf

Keywords

Immunogenity; antibodies persistence; diphteria-tetanus-acellular pertussis vaccination; adolescent; adults;

Abstract

Introduction: In industrialized countries, routine use of pertussis vaccines has shifted the burden of pertussis disease from children to infants, adolescents and adults, leading to the necessity of booster doses.

Materials and methods: We prepared the review following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) with the aim of a) to describe the immunogenity of the main available vaccines for adolescents and adults b) to describe antibodies persistance after immunization with the main vaccines available in childhood and adults and, also, possible co-administration and c) to identify the gold standard for adolescent and adult immunizations.

Results Of 6906 records identified, after removing duplicate records, 12 RCT were included (people aged 11-73): of these 7 studies had only 1 control group, 4 studies had 2 control group and 1 had 5 control group; moreover of the 12 studies included only 2 regarding co-administration and all were about immunogenity. 9 out 12 studies had a Jadad score above 3 points and 10 out 12 meet the criteria of Cocrane Back Review Group Criteria List for Methodological Quality Assessment.

Discussion and conclusion: We found a limited number of good-quality RCTs investigating our object. The five component vaccines, although containing a lower dosage of antigen, are found to be more effective than one components vaccines for prevention. Evidences support the use of 5-components vaccines for booster sessions in adolescence and adulthood.

Introduction: In industrialized countries, routine use of pertussis vaccines has shifted the burden of pertussis disease from children to infants, adolescents and adults, leading to the necessity of booster doses.

Materials and methods: We prepared the review following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) with the aim of a) to describe the immunogenity of the main available vaccines for adolescents and adults b) to describe antibodies persistance after immunization with the main vaccines available in childhood and adults and, also, possible co-administration and c) to identify the gold standard for adolescent and adult immunizations.

Results Of 6906 records identified, after removing duplicate records, 12 RCT were included (people aged 11-73): of these 7 studies had only 1 control group, 4 studies had 2 control group and 1 had 5 control group; moreover of the 12 studies included only 2 regarding co-administration and all were about immunogenity. 9 out 12 studies had a Jadad score above 3 points and 10 out 12 meet the criteria of Cocrane Back Review Group Criteria List for Methodological Quality Assessment.

Discussion and conclusion: We found a limited number of good-quality RCTs investigating our object. The five component vaccines, although containing a lower dosage of antigen, are found to be more effective than one components vaccines for prevention. Evidences support the use of 5-components vaccines for booster sessions in adolescence and adulthood.

https://doi.org/10.15167/2421-4248/jpmh2020.61.4.1832
pdf

References

1. Gabutti G, Rota MC. Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health. 2012;9(12):4626-4638. doi:10.3390/ijerph9124626
2. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016 Jul;29(3):449-86. doi: 10.1128/CMR.00083-15. PMID: 27029594; PMCID: PMC4861987.
3. Mink CM, Yeh SH. Pertussis in adolescents and its prevention using Tdap vaccination. Adolesc Med State Art Rev. 2010 Aug;21(2):220-35, viii. PMID: 21047026.
4. Dalby T, Petersen JW, Harboe ZB, Krogfelt KA. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol. 2010 Sep;59(Pt 9):1029-1036. doi: 10.1099/jmm.0.020826-0. Epub 2010 May 27. PMID: 20508003.
5. Triaxis. Package leaflet: information for the user. Agenzia italiana del farmaco (Italian Medicines Agency). Available at https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_005532_039760_FI.pdf&retry=0&sys=m0b1l3. Last access on 23.10.2020
6. Boostrix. Package leaflet: information for the user. Agenzia italiana del farmaco (Italian Medicines Agency). Available at https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000200_034813_FI.pdf&retry=0&sys=m0b1l3. Last access on 23.10.2020
7. Tribaccine. Package leaflet: information for the user. Agenzia italiana del farmaco (Italian Medicines Agency). Available at https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004314_042607_FI.pdf&retry=0&sys=m0b1l3 . Last access on 23.10.2020
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1-12. PMID: 8721797
9. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Available at: www.cochrane-handbook.org.
10. Carlsson RM, Gustafsson L, Hallander HO, Ljungman M, Olin P, Gothefors L, Nilsson L, Netterlid E. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years. Vaccine. 2015 Jul 17;33(31):3717-25. doi: 10.1016/j.vaccine.2015.05.079.
11. Embree J, Law B, Voloshen T, Tomovici A. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart. Clin Vaccine Immunol. 2015 Mar;22(3):282-90. doi: 10.1128/CVI.00682-14.
12. Halperin SA, Scheifele D, De Serres G, Noya F, Meekison W, Zickler P, Larrivée L, Langley JM, McNeil SA, Dobson S, Jordanov E, Thakur M, Decker MD, Johnson DR. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine. 2012 Jan 20;30(5):974-82. doi: 10.1016/j.vaccine.2011.11.035.
13. McNeil SA, Noya F, Dionne M, Predy G, Meekison W, Ojah C, Ferro S, Mills EL, Langley JM, Halperin SA. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine. 2007 Apr 30;25(17):3464-74. doi: 10.1016/j.vaccine.2006.12.047.
14. Halperin SA, Smith B, Russell M, Scheifele D, Mills E, Hasselback P, Pim C, Meekison W, Parker R, Lavigne P, Barreto L. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J. 2000 Apr;19(4):276-83. doi: 10.1097/00006454-200004000-00003.
15. Jahnmatz M, Ljungman M, Netterlid E, Jenmalm MC, Nilsson L, Thorstensson R. Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine. Clin Vaccine Immunol. 2014 Sep;21(9):1301-8. doi: 10.1128/CVI.00280-14.
16. Halperin SA, Smith B, Russell M, Hasselback P, Guasparini R, Skowronski D, Meekison W, Parker R, Lavigne P, Barreto L. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine. 2000 Jan 31;18(14):1312-9. doi: 10.1016/s0264-410x(99)00415-6.
17. Halperin SA, Donovan C, Marshall GS, Pool V, Decker MD, Johnson DR, Greenberg DP; Tdap Booster Investigators. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. J Pediatric Infect Dis Soc. 2019 May 11;8(2):105-114. doi: 10.1093/jpids/pix113.
18. Sirivichayakul C, Chanthavanich P, Limkittikul K, Siegrist CA, Wijagkanalan W, Chinwangso P, Petre J, Hong Thai P, Chauhan M, Viviani S. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults. Hum Vaccin Immunother. 2017 Jan 2;13(1):136-143. doi: 10.1080/21645515.2016.1234555.
19. Van der Wielen M, Van Damme P, Joossens E, François G, Meurice F, Ramalho A. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (Tdap) vaccine in adults. Vaccine. 2000 Apr 14;18(20):2075-82. doi: 10.1016/s0264-410x(99)00568-x.
20. Thierry-Carstensen B, Dalby T, Stevner MA, Robbins JB, Schneerson R, Trollfors B. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013 Oct 25;31(45):5178-91. doi: 10.1016/j.vaccine.2013.08.034.
21. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, Wang E, Mills E. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005 Jun 22;293(24):3003-11. doi: 10.1001/jama.293.24.3003. Epub 2005 Jun 2. Erratum in: JAMA. 2005 Dec 28;294(24):3092. PMID: 15933223.
22. Barkoff AM, Gröndahl-Yli-Hannuksela K, Vuononvirta J, Mertsola J, Kallonen T, He Q. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine. 2012 Nov 6;30(48):6897-902. doi: 10.1016/j.vaccine.2012.09.003. Epub 2012 Sep 13. PMID: 22981763.
23. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996 Feb 8;334(6):349-55. doi: 10.1056/NEJM199602083340602. Erratum in: N Engl J Med 1996 May 2;334(18):1207.
24. Ohfuji S, Okada K, Nakano T, Ito H, Hara M, Kuroki H, Hirota Y. Effectiveness of acellular pertussis vaccine in a routine immunization program: a multicenter, case-control study in Japan. Vaccine. 2015 Feb 18;33(8):1027-32. doi: 10.1016/j.vaccine.2015.01.008.
25. Keijzer-Veen MG, Holty-van der Wekken L, Juttmann RE, de Groot R, Rümke HC. Reactogenicity of acellular pertussis vaccine in 4-year-olds in The Netherlands. Vaccine. 2004 Sep 3;22(25-26):3256-7. doi: 10.1016/j.vaccine.2004.03.010.
26. Pourakbari B, Moradi B, Mirzaee F, Mahmoudi S, Teymuri M, Mamishi S. Seroprevalence of antibodies to diphtheria, tetanus and pertussis among healthy adolescents and adults in Iran. Roum Arch Microbiol Immunol. 2013 Oct-Dec;72(4):250-4. PMID: 24923108.
27. Afari EA, Kamiya Y, Nkrumah FK, Dunyo SK, Akpedonu P, Kamiya H, Fukai F. Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana. Ann Trop Paediatr. 1996 Mar;16(1):39-48. doi: 10.1080/02724936.1996.11747802. PMID: 8787364.
28. Halperin SA, Mills E, Barreto L, Pim C, Eastwood BJ. Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J. 1995 Sep;14(9):792-7. doi: 10.1097/00006454-199509000-00012. PMID: 8559630.
29. Fortner KB, Swamy GK, Broder KR, Jimenez-Truque N, Zhu Y, Moro PL, Liang J, Walter EB, Heine RP, Moody MA, Yoder S, Edwards KM. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. Vaccine. 2018 Oct 8;36(42):6354-6360. doi: 10.1016/j.vaccine.2018.07.012.
30. Halperin SA, McNeil S, Langley J, Blatter M, Dionne M, Embree J, Johnson R, Latiolais T, Meekison W, Noya F, Senders S, Zickler P, Johnson DR. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine. 2011 Oct 26;29(46):8459-65. doi: 10.1016/j.vaccine.2011.07.068.
31. Asatryan A, Meyer N, Scherbakov M, Romanenko V, Osipova I, Galustyan A, Shamsheva O, Latysheva T, Myasnikova T, Baudson N, Dodet M, Xavier S, Harrington L, Kuznetsova A, Campora L, Van den Steen P. Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. Hum Vaccin Immunother. 2020 Aug 26:1-8. doi: 10.1080/21645515.2020.1796423.
32. Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, Hallander HO. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol. 2010 May;17(5):741-7. doi: 10.1128/CVI.00469-09.
33. Collins CL, Salt P, McCarthy N, Chantler T, Lane L, Hemme F, Diggle L, Buttery J, Kitchin NR, Moxon ER, Pollard AJ. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine. 2004 Oct 22;22(31-32):4262-9. doi: 10.1016/j.vaccine.2004.04.027.
34. Hori H, Afari EA, Akanmori BD, Kamiya Y, Sakatoku H, Nkrumah FK, Kamiya H, Chazono M, Fukai K. A randomized controlled trial of two acellular pertussis-diphtheria-tetanus vaccines in primary immunization in Ghana: antibody responses and adverse reactions. Ann Trop Paediatr. 1994;14(2):91-6. doi: 10.1080/02724936.1994.11747699.
35. Knuf M, Zepp F, Meyer C, Grzegowski E, Wolter J, Riffelmann M, Wirsing von König CH. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine. 2006 Mar 15;24(12):2043-8. doi: 10.1016/j.vaccine.2005.11.024.
36. Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine. 2007 Jan 22;25(6):1121-5. doi: 10.1016/j.vaccine.2006.09.053.
37. Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Rauh W, Clemens R. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996 Jan 3;275(1):37-41.
38. Pichichero ME, Green JL, Francis AB, Marsocci SM, Murphy AM, Buscarino C. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Scand J Infect Dis. 1996;28(2):159-63. doi: 10.3109/00365549609049068.
39. Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin. 2008 May-Jun;4(3):203-9. doi: 10.4161/hv.4.3.5290.
40. Trollfors B, Knutsson N, Taranger J, Mark A, Bergfors E, Sundh V, Lagergård T. Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose. Eur J Pediatr. 2006 Jan;165(1):14-8. doi: 10.1007/s00431-005-1763-3.
41. Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine. 2000 Apr 28;18(21):2295-306. doi: 10.1016/s0264-410x(99)00539-3.
42. Tomovici A, Barreto L, Zickler P, Meekison W, Noya F, Voloshen T, Lavigne P. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine. 2012 Mar 30;30(16):2647-53. doi: 10.1016/j.vaccine.2012.02.013.
43. Pool V, Tomovici A, Johnson DR, Greenberg DP, Decker MD. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA. Vaccine. 2018 Apr 19;36(17):2282-2287. doi: 10.1016/j.vaccine.2018.03.029.
44. Center of Disease Control (CDC). Safety information. Diphtheria, Tetanus, and Pertussis Vaccines. Available on https://www.cdc.gov/vaccinesafety/vaccines/dtap-tdap-vaccine.html#:~:text=CDC%20recommends%3A,or%20Td%20every%2010%20years. Last access on 29 October 20.
45. Muse D, Christensen S, Bhuyan P, Absalon J, Eiden JJ, Jones TR, York LJ, Jansen KU, O'Neill RE, Harris SL, Perez JL. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents. Pediatr Infect Dis J. 2016 Jun;35(6):673-82. doi: 10.1097/INF.0000000000001124. PMID: 26974889.
46. Tashani M, Alfelali M, Barasheed O, Alqahtani AS, Heron L, Wong M, Rashid H, Findlow H, Borrow R, Booy R. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial. Vaccine. 2018 Jul 5;36(29):4375-4382. doi: 10.1016/j.vaccine.2018.04.033. Epub 2018 Jun 5. PMID: 29880243.
47. Schilling A, Parra MM, Gutierrez M, Restrepo J, Ucros S, Herrera T, Engel E, Huicho L, Shew M, Maansson R, Caldwell N, Luxembourg A, Ter Meulen AS. Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines. Pediatrics. 2015 Sep;136(3):e563-72. doi: 10.1542/peds.2014-4199. Epub 2015 Aug 3. PMID: 26240207.
48. Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 2009 Dec;1(1):51-4. PMID: 22263004; PMCID: PMC3256489
49. Poolman JT, Hallander HO. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines. 2007 Feb;6(1):47-56. doi: 10.1586/14760584.6.1.47.